Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241411829 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Ioannis Ntanasis-Stathopoulos und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 157 72 Athens, Greece. Hauptthemen laut MEDLINE: Multiple Myeloma, Antineoplastic Agents. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
B-cell maturation antigen (BCMA) is a promising therapeutic target for multiple myeloma (MM). The aim of this study was to assess the effectiveness and tolerability of monotherapy with the conjugated anti-BCMA monoclonal antibody belantamab mafodotin in triple-class refractory patients with MM in real-world practice. Patients refractory to at least one proteasome inhibitor, one immunomodulatory drug, and one anti-CD38 monoclonal antibody received belantamab mafodotin at 2.5 mg/kg intravenously every 3 weeks. Overall, 27 patients with a median age of 65 years (range 41–81) were included. Of these, 52% were male and the median number of prior lines of treatment was 5 (4–10). The overall response rate (partial response or better) was 52%, whereas the disease control rate (stable disease or better) was 70%. The median progression-free survival (PFS) was 2 months (95%CI: 0–7), whereas the median PFS among the responders was 12 months (95%CI: 6–18). Regarding the toxicity profile, the most common toxicity was eye toxicity, in 44% of the patients. Keratopathy grade 2–3 was reported in 33.3% of the patients. In conclusion, belantamab mafodotin showed a safety and efficacy profile consistent with the results of the registrational study. Importantly, heavily pretreated patients who responded to treatment derived a substantial survival benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 157 72 Athens, Greece.
ORCID-Profile: Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vassiliki Spiliopoulou, Efstathios Kastritis, Evangelos Terpos, Meletios-Athanasios Dimopoulos
Zitieren
APA
Ntanasis-Stathopoulos, I., Malandrakis, P., Fotiou, D., Migkou, M., Theodorakakou, F., Roussou, M., Eleutherakis-Papaiakovou, E., Spiliopoulou, V., Kastritis, E., Terpos, E., Dimopoulos, M. A., & Gavriatopoulou, M. (2023). Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241411829
Vancouver
Ntanasis-Stathopoulos I, Malandrakis P, Fotiou D, Migkou M, Theodorakakou F, Roussou M, et al. Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241411829
BibTeX
@article{NtanasisStathopoulos2023,
author = {Ntanasis-Stathopoulos, Ioannis and Malandrakis, Panagiotis and Fotiou, Despina and Migkou, Magdalini and Theodorakakou, Foteini and Roussou, Maria and Eleutherakis-Papaiakovou, Evangelos and Spiliopoulou, Vassiliki and Kastritis, Efstathios and Terpos, Evangelos and Dimopoulos, Meletios-Athanasios and Gavriatopoulou, Maria},
title = {Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241411829}
}
EUVIMED